Risk Factors Update Summary
- Accumulated deficit increased from approximately $73 million to $80 million as of December 31, 2023.
- Sales of DYAI-100 SARS-CoV-2 vaccine candidate completed Phase 1 clinical trial in South Africa.
- Potential future regulations limiting genetically engineered product sales could harm business.
- Currency fluctuations due to research in Europe may negatively affect revenue and financial position.
- Increased control by officers and principal stockholders, now controlling approximately 35% of outstanding shares.
- Dependence on third parties for research and financial information may impact reporting accuracy.
- Increased scrutiny on ESG practices may impose additional costs or expose to new risks.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1213809&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.